Aethlon Medical Provides Progress Report to Wall Street

Aethlon Medical, Inc., (OTCBB:AEMD):

— Gives interim update of first human safety study of its

Hemopurifier(TM)

— Announces the CDC has initiated testing of Aethlon’s

technology as a potential treatment against the Ebola virus

— Discusses the continued enhancement of its leadership team

Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced that its Chairman and CEO, James A. Joyce presented a company update yesterday at The New York Society of Security Analysts 9th Annual Biotech/Specialty Pharma Conference.

Aethlon’s CEO provided the following updates:

— Interim results of the company’s first human safety study of

its Hemopurifier(TM), which is designed to augment the immune

response by clearing viruses and toxins from circulation, have

shown no material adverse events in the first three patients

treated. This is a small safety study of Hepatitis-C infected

patients, in which patients were treated three times per week

for four hours each day at the Apollo Hospital in New Delhi,

India. The Apollo Hospital system is the largest in Asia, and

forth largest in the world. Additional results will be

provided upon completion of the study in the first quarter of

2006.

— The company also announced that the Centers for Disease

Control & Prevention (CDC), the U.S. agency at the forefront

of public health efforts to prevent and control infectious

diseases, has initiated early-stage testing of Aethlon’s

Hemopurifier(TM) as a potential treatment against the Ebola

virus.

— Aethlon also discussed the expansion of its leadership team as

part of the transition from pure research and development to

commercialization. In this regard, the company has attracted

experienced talent to lead its finance and communications

activities and has engaged formal representation in

Washington, D.C. to help advance federal government and

biodefense initiatives.

         —  James Dorst, who joined Aethlon as Chief Financial             Officer, brings 20 years of senior management experience             in finance, operations, planning and business transactions             in both the public and private marketplaces. Prior to             joining Aethlon, Mr. Dorst was Vice President of Finance             and Operations for VerdiSoft Corporation, a             developmental-stage mobile-software developer recently             acquired by YAHOO, INC.          —  Jeffrey Richardson, has been appointed Senior Director,             Communications, has nearly 20 years of senior leadership             in international public relations for research-based             medical companies. Prior to joining Aethlon, Mr.             Richardson was Director, Global Public Relations for             Amgen, the world’s largest biotechnology company.          —  Aethlon disclosed it has engaged McKenna Long & Aldridge             LLP to assist in obtaining government grants and             contracts. McKenna Long & Aldridge has an impressive track             record of producing results for clients in the emerging             biodefense industry. 

About Aethlon Medical

Aethlon Medical is pioneering the development of immunotherapeutic devices able to mimic the immune response of clearing viruses and viral toxins from circulation. The Company’s lead product, the Hemopurifier(TM), converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The Hemopurifier(TM) is targeted to treat acute and chronic infectious diseases, including, drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV), and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare, and dialysis industries. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.